IFRX InflaRx N.V.

BEARISH Impact: 5/10 424B5
Horizon weeks Filed May 6, 2026 Processed 1mo ago SEC 0001140361-26-019288
Notable filing: 424B5
Latest settled — T+20d ⚠ clustered
IFRX ▼ -22.26% at T+20d
SHORT call ✓ call won +22.26% · α vs SPY +25.40% · entry $2.65 → $2.06
Next anchor: T+60d in 7w
Currently $1.60 · +39.62% from $2.65 entry (call sign-flipped)
Entry anchored
May 6, 03:59 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +0.83%
$2.65
settled 5w ago
T+5d
-4.91%
call +4.91% · α +6.41%
$2.52
settled 4w ago
T+20d
-22.26%
call +22.26% · α +25.40%
$2.06
settled 9d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

InflaRx filed a preliminary prospectus supplement for an underwritten offering of ordinary shares. The size and pricing are not yet disclosed, but the company will use proceeds to advance pipeline activities and for working capital. Existing shareholders will face dilution, and the filing is preliminary with many placeholder amounts.

Actionable Insight

Wait for final pricing and size of the offering before taking a position. The stock may decline on the announcement of larger-than-expected dilution. Monitor the prospectus supplement for definitive terms and the NASDAQ filing for pricing details.

Key Facts

  • Offering of ordinary shares, size and price not disclosed (preliminary filing)
  • As of March 31, 2026, net tangible book value was $41.5M ($0.57/share) on 72,292,859 shares outstanding
  • Last sale price on May 5, 2026 was $1.97 per share
  • Company had total funds available of €39.7M as of March 31, 2026
  • Proceeds to fund pipeline activities and working capital; cash runway projected through 2029
  • Restructuring announced in January 2026; CMO resigned effective August 2026

Financial Impact

Offering size and price not yet determined; dilution will depend on final terms

dilutionworking capital

Risk Factors

  • Significant dilution to existing shareholders
  • Uncertainty around offering size and pricing
  • Pre-revenue biotech with ongoing cash burn and restructuring

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001140361-26-019288
Document: 0001140361-26-019288-index-headers.html0001140361-26-019288
Document: 0001140361-26-019288-index.html0001140361-26-019288
Document: 0001140361-26-019288.txt0001140361-26-019288
12 reports for IFRX
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +142.72%Apr 9, 2026
Filters
Rows
Reports for IFRX — sortable, filterable
Type Now
May 6, 2026
5w ago
424B5
BEARISH ★ 5/10
$2.65 $2.06▲ +22.26%▲ +25.40%$1.60 (+39.62%)
May 6, 2026
5w ago
6-K
BULLISH ★ 7/10
$2.50 $2.06▼ −17.60%▼ −20.38%$1.60 (−36.00%)
May 6, 2026
5w ago
Press Release
NEUTRAL ★ 5/10
$2.50 $2.06▼ −17.60%▼ −20.38%$1.60 (−36.00%)
May 6, 2026
5w ago
6-K
NEUTRAL ★ 4/10
$2.50 $2.06▼ −17.60%▼ −20.38%$1.60 (−36.00%)
May 4, 2026
5w ago
6-K
NEUTRAL ★ 3/10
$1.97 $2.17▲ +10.15%▲ +5.20%$1.60 (−18.78%)
May 1, 2026
6w ago
Press Release
NEUTRAL ★ 2/10
$2.10 $2.28▲ +8.57%▲ +3.29%$1.60 (−23.81%)
Apr 23, 2026
7w ago
6-K
NEUTRAL ★ 5/10
$1.48 $2.47▲ +66.89%▲ +62.87%$1.60 (+8.11%)
Apr 9, 2026
9w ago
Press Release
BULLISH ★ 7/10
$1.03 $2.50▲ +142.72%▲ +135.15%$1.60 (+55.34%)
Mar 19, 2026
12w ago
Press Release
BULLISH ★ 7/10
$0.9100 $1.59▲ +74.73%▲ +67.10%$1.60 (+75.82%)
Mar 18, 2026
12w ago
Press Release
BULLISH ★ 8/10
$0.8800 $1.20▲ +36.36%▲ +30.32%$1.60 (+81.82%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (48h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access